** Shares of medical device maker Tivic Health Systems TIVC.O rise 232.6% to $11.82 premarket

** TIVC says it provided briefings at the White House and FDA which secured positive interest in potential military and defense applications for its biologic and bioelectronic product candidates

** Both meetings were held last week in Washington D.C. - TIVC

** Separately, co says it discussed the potential for expedited pathways and support for export opportunities for its lead experimental immunotherapy drug called entolimod

** Entolimod is being tested in a late-stage study in patients to treat acute radiation syndrome $(ARS.UK)$, a condition caused by exposure to high doses of ionizing radiation

** As of last close, TIVC had fallen 40.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))